Philippe Moreau, MD of the University Hospital, Nantes, France, presents some very exciting results showing the use of daratumumab in the front line setting. Trials such as the CASTOR and POLLUX, have previously shown outstanding results for daratumumab in combination with lenalidomide and bortezomib in the relapsed setting. Prof. Moreau explains that daratumumab is now being used in the front line setting in the ALCYONE study. Promising results have shown an improvement in response rate and an improved primary endpoint of progression free survival. Furthermore, the reduction in the risk of death or progression was reduced by 50%.
Recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates